Thiazolidinedione (TZD) reference compound. Selective PPARgamma agonist. Selectively activates PPARgamma-1. Anti-diabetic , decreasing insulin resistance in adipose tissue. Is about one tenth as potent as rosiglitazone. Lipid metabolism modulator. Estrogen synthesis inhibitor. NF-kappaB inhibitor. Neuroprotective.
Storage and Stability:
Short-term Storage: +4°C
Long-term Storage: -20°C
Stable for at least 2 years after receipt when stored at -20°C.
Purity: >98% (1H-NMR)
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference: |
Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone: J. Sakamoto, et al.; BBRC 278, 704 (2000)
The PPARs: from orphan receptors to drug discovery: T.M. Willson, et al.; J. Med. Chem. 43, 527 (2000)
The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones: T.M. Willson, et al.; J. Med. Chem. 39, 665 (1996)
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma): J.M. Lehmann, et al.; J. Biol. Chem. 270, 12953 (1995)
benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents: B.C. Cantello, et al.; J. Med. Chem. 37, 3977 (1994)
Pioglitazone: beyond glucose control: P. de Pablos-Velasco; Expert Rev. Cardiovasc. Ther. 8, 1057 (2010) Review
Rosiglitazone and Pioglitazone Inhibit Estrogen Synthesis in Human Granulosa Cells by Interfering with Androgen Binding to Aromatase: D. Seto-Young, et al.; Horm. Metab. Res. Epub ahead of print, (2011)
Pioglitazone suppresses the lipopolysaccharide-induced production of inflammatory factors in mouse macrophages by inactivating NF-kappaB: C. Ao, et al.; Cell Biol. Int. 34, 723 (2010)
Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-kappaB signaling pathway: H.L. Zhang, et al.; Neuroscience 176, 381 (2011)
|Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.|